NATICK, Mass., May 7 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced CE Mark approval and market launch of its ALTRUA(TM) family of pacemakers. ALTRUA is Boston Scientific's most advanced pacemaker and delivers enhanced therapies while maintaining its small size and battery longevity. It is the first Boston Scientific-branded pacemaker to treat bradycardia, a condition in which the heart beats too slowly -- usually less than 60 beats per minute -- depriving the body of sufficient oxygen.
"European approval of Boston Scientific's ALTRUA family of pacemakers is the latest example of the significant progress we have made rebuilding our CRM organization and reinvigorating our product pipeline," said Fred Colen, Executive Vice President, Operations and Technology, CRM. "ALTRUA's innovative technology -- enabling physicians to adjust the therapy to meet the needs of their patients -- demonstrates our renewed focus on treating bradycardia."
The ALTRUA pacemaker provides physicians with a number of diagnostic
and therapeutic capabilities that enable them to tailor the therapy to
specific patient requirements:
-- Multiple Atrial Ventricular (AV) Delay programming options: These
options are designed to reduce unnecessary right ventricular (RV)
pacing, without dropping ventricular beats, a key distinction from
other competitive RV pacing algorithms. The ALTRUA 50 and 60 series
also include an enhanced AV search hysteresis feature, now with an
extendable AV delay out to 400 milliseconds, providing physicians with
additional flexibility to tailor device programming for unique patient
-- Minute Ventilation (MV) Bl
|SOURCE Boston Scientific Corporation|
Copyright©2008 PR Newswire.
All rights reserved